RxDoctor Payments Data

Michael Feldman, DO

Family Medicine · Village Of Palmetto Bay, FLNPI 1578662110

Payments from drug & device makers

$228,262in general payments, 2019–2025

Across 46 payments — averaging $4962.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$72K
  • E.r. Squibb & Sons, L.L.C.$42K
  • AstraZeneca$31K
  • Eli Lilly$23K
  • Eisai Inc.$20K
  • GSK$12K
  • plus $27K from 5 others
$704in research payments, 2019–2025

Across 12 payments — averaging $58.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$704

What the payments were for

  • Food & beverage$26398%
  • Education$62%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$228,262 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,353
Medicare patients
155
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$51,700
JardianceEmpagliflozin30$41,931
MounjaroTirzepatide21$22,483
EliquisApixaban16$13,740
Breo ElliptaFluticasone/Vilanterol22$10,291
Rosuvastatin Calcium247$3,348
Levothyroxine Sodium184$2,524
Atorvastatin Calcium241$2,441
Famotidine106$2,228
Losartan Potassium165$1,854
Omeprazole57$1,609
Metoprolol Succinate60$1,354
Nifedipine ErNifedipine35$1,149
Amlodipine Besylate174$1,057
Metformin Hcl160$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$12,450$10,29122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Village Of Palmetto Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →